|1.||Rosenberg, Steven A: 56 articles (05/2015 - 01/2002)|
|2.||Atkins, Michael B: 37 articles (07/2015 - 06/2002)|
|3.||Restifo, Nicholas P: 26 articles (05/2015 - 08/2003)|
|4.||Tsokos, George C: 23 articles (09/2014 - 05/2002)|
|5.||McDermott, David F: 22 articles (02/2015 - 10/2002)|
|6.||Neri, Dario: 21 articles (08/2015 - 03/2002)|
|7.||Yang, James C: 21 articles (05/2015 - 01/2002)|
|8.||Lissoni, P: 21 articles (05/2008 - 01/2000)|
|9.||Dudley, Mark E: 20 articles (05/2015 - 05/2002)|
|10.||Kaufman, Howard L: 19 articles (04/2015 - 03/2002)|
07/01/2005 - "Local interleukin 2 therapy is most effective against cancer when injected intratumourally."
11/20/1997 - "However, in a short-term therapy model, continued IL-2 expression was most effective against 3-day established tumors. "
03/23/1994 - "Because IL-2 does not have a direct effect on cancer cells but rather mediates its antitumor activity by altering host immune reactions, these data represent the best available evidence that immunologic therapy for cancer can be effective in selected patients."
04/07/1993 - "Our results suggest that induction of anti-tumor immune response by local IL-2 production is most effective when the helper cytokine is secreted by the tumor cell. "
01/01/1993 - "On the other hand, several groups have shown that application of intratumoral low doses of IL-2 can be highly effective against cancer and without toxic side-effects. "
|2.||Melanoma (Melanoma, Malignant)
04/01/2006 - "A variety of immunotherapeutic approaches have shown activity in patients with metastatic melanoma with the best results being observed with interleukin 2 (IL-2). "
08/01/2003 - "Adjuvant treatment of intermediate- and high-risk melanoma patients with low-dose IFNalpha2b and IL-2 is safe and well tolerated by most patients, but it does not improve disease-free or overall survival."
12/01/2015 - "Erratum to: Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease."
01/01/2015 - "Pathologic complete response to intralesional interleukin-2 therapy associated with improved survival in melanoma patients with in-transit disease."
01/01/2013 - "This study assessed the safety and therapeutic efficacy of high-dose IL-2 in patients ≥65 years of age with metastatic melanoma and RCC. "
|3.||Neoplasm Metastasis (Metastasis)
10/01/2008 - "CT showed a complete response on lung metastases and lymph node metastases and marked decrease of liver metastases after the first course of IL-2. "
07/01/1999 - "The median disease-free interval in the brain after resection of a single metastasis was 21, 7, and 3 months for patients achieving a complete response, partial response, and no response (CR, PR, and NR) to IL-2 therapy, respectively. "
01/01/1995 - "Of 33 patients, one achieved a complete remission (response duration, 24 months) and two patients presented with partial remissions (median response duration, 7 months) of pulmonary metastases upon rIFN-alpha/5-FU after failing SC recombinant interleukin-2 (rIL-2) and rIFN-alpha. "
12/01/1986 - "A single patient with pulmonary and hepatic metastases showed marked decrease in these lesions with intraperitoneal IL-2 treatment. "
04/01/2004 - "Inhalation of IL-2 for the treatment of pulmonary metastases in RCC is feasible, tolerable and beneficial in controlling progressive disease for considerable periods of time. "
|4.||Renal Cell Carcinoma (Grawitz Tumor)
02/01/2000 - "With prolonged follow-up, treatment with high-dose recombinant IL-2 remains extremely effective for a subset of patients with metastatic renal cell carcinoma."
09/01/2011 - "Although the new agents result in a progression-free survival benefit, high-dose IL-2 remains the only agent with proven efficacy in producing durable complete and partial responses in patients with metastatic renal cell carcinoma (RCC). "
11/01/2005 - "Interleukin-2 (IL-2) has been shown to produce durable complete remission in patients with renal cell carcinoma (RCC). "
09/01/1999 - "High dose i. v. IL-2 therapy in metastatic renal cell carcinoma has been proven effective . "
01/17/1990 - "A phase II trial of intermittent high-dose recombinant interleukin-2 (rIL-2) was initiated to evaluate the response rate, remission duration, and toxic effects in patients with measurable metastatic renal cell carcinoma. "
04/15/2006 - "These data indicate that IL-2 treatment in combination with effective ART is beneficial for the restoration of innate NKT cell immunity in patients with primary HIV-1 infection."
01/01/2002 - "However, after secondary infection, SC animals displayed significantly greater IL-2 levels in serum and the duodenum compared with strain TK. "
10/01/2009 - "Protection against subsequent malarial infection tended to be associated with a higher percentage of individuals with CSP-specific IL-2 in the supernatant (P = 0.053) and with higher CSP-specific IFN-gamma-producing CD8(+) T-cell responses (P = 0.07). "
06/01/2008 - "Furthermore, not only the ablation of negative signals but also the addition of stimulatory signals, such as interleukin 2 (IL-2), might prove to be a potentially promising strategy to augment the efficacy of therapeutic vaccination against chronic viral infections."
03/01/1987 - "The protective effect was fully inducible as early as 1 h after IL-2 administration and was effective against various strains of gram-negative bacteria, indicating that the probable mode of action represents control of the establishment of infection by increased activity of the nonspecific host defense mechanisms. "
|3.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|4.||Interferon-alpha (Interferon Alfa)
|5.||Interferon-gamma (Interferon, gamma)
|6.||Interleukin-12 (IL 12)
|8.||Interleukin-4 (Interleukin 4)
|9.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
|10.||Interleukin-10 (Interleukin 10)
|2.||Drug Therapy (Chemotherapy)
|5.||Bone Marrow Transplantation (Transplantation, Bone Marrow)